Impact of Chronic Obstructive Pulmonary Disease on Immune-based Treatment for Lung Cancer. Moving toward Disease Interception
- 1 February 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 197 (3) , 278-280
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Erratum: Targeting neoantigens to augment antitumour immunityNature Reviews Cancer, 2017
- Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell AnalysesCell, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patientsOncoImmunology, 2016
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- The Non–Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient OutcomeAmerican Journal of Respiratory and Critical Care Medicine, 2015
- New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escapeCurrent Opinion in Immunology, 2014
- Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T CellsCancer Research, 2014
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- The Immunobiology of Cancer Immunosurveillance and ImmunoeditingImmunity, 2004